Clostridium Difficile Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Ursodeoxycholic Acid in C. Difficile Infection
Condition: Clostridioides Difficile Infection Intervention: Drug: Ursodeoxycholic acid Sponsor: Nottingham University Hospitals NHS Trust Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 2, 2022 Category: Research Source Type: clinical trials

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
ECOSPOR IV study shows favorable safety profile through 24-week follow-up, consistent with the safety profile observed in ECOSPOR III study 91.3% sustained clinical response achieved at eight weeks in overall population with consistent results in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 7, 2022 Category: Pharmaceuticals Source Type: clinical trials

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile
Condition: C. Difficile Colonization Interventions: Other: Arm 1: Routine care; Other: Arm 2: Preemptive C. difficile infection prevention bundle Sponsors: Brigham and Women's Hospital; Harvard Pilgrim Health Care Institute; Centers for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2022 Category: Research Source Type: clinical trials

LMN-201 for Prevention of C. Difficile Infection Recurrence
Condition: Clostridioides Difficile Infection Interventions: Drug: LMN-201; Drug: Placebo Sponsor: Lumen Bioscience, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2022 Category: Research Source Type: clinical trials